ULTRAVIST 300 62 % — DIN 02078600
IOPROMIDE : 62 % · BAYER INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ULTRAVIST 300?
ULTRAVIST 300 62 % contains IOPROMIDE : 62 %. It is listed in the Health Canada Drug Product Database under DIN 02078600, held by BAYER INC, supplied as SOLUTION for INTRAVASCULAR administration. Health Canada currently lists it as marketed, status dated 19-Apr-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ULTRAVIST 300 used for?
Intravascular use for radiographic contrast procedures (CT, urography, angiography, etc.) and visualization of body cavities (arthrography, hysterosalpingography).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Iopromide cost around the world?
Iopromide is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 10 | 12 | ZAR███.██ |
| Saudi Arabia | public | 3 | 7 | SAR███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| Hungary | producer price (ex-factory) | 2 | 6 | HUF███.██ |
| Morocco | PPV (public price) | 1 | 6 | MAD███.██ |
| Bahrain | retail (max) | 1 | 2 | BHD███.██ |
39 pack listings across 23 brand entries and 5 price bases, refreshed 05 Sep 2026. Ranges span every Iopromide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Iopromide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Iopromide — 3 DINs, of which 2 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAYER INC | 3 | 2 | ULTRAVIST 240, ULTRAVIST 300, ULTRAVIST 370 | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 62 % |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVASCULAR |
| Pack configuration (monograph) | Vials of 50, 100, 150 mL; Pharmacy Bulk Vials of 200 and 500 mL. Not all presentations may be available. |
| Storage | Not explicitly detailed in provided text snippet (refers to section 11), but typically 15-30°C for such products. Use immediately after withdrawal. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Iopromide |
|---|---|
| ATC code | V08AB05 |
| AHFS class | 36:68.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02078600 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2078600 |
| Brand name | ULTRAVIST 300 |
| Generic / active ingredient | IOPROMIDE : 62 % |
| Market authorization holder | BAYER INC |
| Health Canada schedule | Ethical |
| ATC code | V08AB05 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V08AB |
| Current status | MARKETED |
| Status date | 19-Apr-2007 |
| Original market date | 1994-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Dosage depends on age, weight, cardiac output, and procedure. Administer at body temperature. Observe patient for 30 mins post-injection. Do not exceed recommended doses.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Myelography, cerebral ventriculography, cisternography; manifest hyperthyroidism; known hypersensitivity; intrathecal use; preparatory dehydration in pediatric patients.
Warnings and precautions
Serious/fatal hypersensitivity reactions possible. Risk of thromboembolic events, thyroid storm, hypertensive crisis in pheochromocytoma, and contrast-induced nephropathy.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ULTRAVIST 370 | 77 % | SOLUTION | BAYER INC | MARKETED | 02078619 |
| ULTRAVIST 240 | 50 % | SOLUTION | BAYER INC | CANCELLED POST MARKET | 02078597 |
2 · Same class — other molecules in ATC V08AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Iopamidol | IOPAMIDOL INJECTION USP · ISOVUE 128 INJ 26% · ISOVUE 128 INJECTION · ISOVUE 200 INJ 41% · +8 more | 15 | 5 | Yes |
| Iodixanol | IODIXANOL INJECTION 270 · IODIXANOL INJECTION 320 · VISIPAQUE 270 · VISIPAQUE 320 | 4 | 4 | Yes |
| Iohexol | OMNIPAQUE 180 · OMNIPAQUE 180 LIQ SAR 388MG/ML · OMNIPAQUE 240 · OMNIPAQUE 240 LIQ IV SAR 518MG/ML · +4 more | 8 | 3 | Yes |
| Iopromide | ULTRAVIST 240 · ULTRAVIST 300 · ULTRAVIST 370 | 3 | 2 | Yes |
| Ioversol | OPTIRAY 160 · OPTIRAY 160 (ULTRAJECT) · OPTIRAY 240 · OPTIRAY 240 (ULTRAJECT) · +7 more | 11 | 0 | Not in Canada |
| Iotrolan | OSMOVIST 240 - LIQ INT 513MG/ML · OSMOVIST 300 - LIQ INT 641MG/ML | 2 | 0 | Not in Canada |
| Ioxaglic Acid | HEXABRIX 200 · HEXABRIX 320 | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V08A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V08AA | Diatrizoic Acid · Iotalamic Acid · Ioxitalamic Acid · Watersol., Nephrotropic, High Osm. X-Ray Contr. Media | 41 | 1 |
| V08AD | Ethyl Esters Of Iodised Fatty Acids · Iopydol | 2 | 1 |
| V08AC | Adipiodone · Iopanoic Acid · Sodium Iopodate | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ULTRAVIST 300 called?
The same molecule, Iopromide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ULTRAVIST | Latin | Bahrain, Morocco, Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.